These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7404075)

  • 1. Monitoring regularity of drug intake in tuberculous patients by means of simple urine tests.
    Burkhardt KR; Nel EE
    S Afr Med J; 1980 Jun; 57(24):981-5. PubMed ID: 7404075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low level of compliance with tuberculosis treatment in children: monitoring by urine tests.
    Palanduz A; Gültekin D; Erdem E; Kayaalp N
    Ann Trop Paediatr; 2003 Mar; 23(1):47-50. PubMed ID: 12648324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attendance versus compliance with tuberculosis treatment in an occupational setting--a pilot study.
    Mqoqi NP; Churchyard GA; Kleinschmidt I; Williams B
    S Afr Med J; 1997 Nov; 87(11):1517-21. PubMed ID: 9472274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.
    Ellard GA; Ellard DR; Allen BW; Girling DJ; Nunn AJ; Teo SK; Tan TH; Ng HK; Chan SL
    Am Rev Respir Dis; 1986 Jun; 133(6):1076-80. PubMed ID: 3717760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests.
    Palanduz A; Gultekin D; Kayaalp N
    Pediatr Pulmonol; 2003 Jul; 36(1):55-7. PubMed ID: 12772224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda.
    Meissner PE; Musoke P; Okwera A; Bunn JE; Coulter JB
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):903-8. PubMed ID: 12365577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet.
    Cowie RL; Brink BA
    S Afr Med J; 1990 Apr; 77(8):390-1. PubMed ID: 2184527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
    Hong Kong Chest Service/British Medical Research Council
    Am Rev Respir Dis; 1989 Dec; 140(6):1618-22. PubMed ID: 2604291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong.
    Chan SL; Wong PC; Tam CM
    Tuber Lung Dis; 1994 Aug; 75(4):245-50. PubMed ID: 7949069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring the ingestion of anti-tuberculosis drugs by simple non-invasive methods.
    Sirgel FA; Maritz JS; Venter A; Langdon G; Smith PJ; Donald PR
    Int J Pharm; 2006 Jan; 307(2):182-7. PubMed ID: 16303269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tolerability and efficacy of a 6-month antituberculosis regimen containing rifampicin, isoniazid and pyrazinamide.
    Kleeberg HH; Swart DJ; Carey SM
    S Afr Med J; 1983 Oct; 64(18):693-6. PubMed ID: 6623275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.